Stay updated on Teriflunomide in Pediatric MS Clinical Trial
Sign up to get notified when there's something new on the Teriflunomide in Pediatric MS Clinical Trial page.

Latest updates to the Teriflunomide in Pediatric MS Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.0%
- Check16 days agoChange DetectedThe page has undergone significant content changes, including the removal of detailed study objectives and participant eligibility criteria for a clinical trial on teriflunomide in pediatric multiple sclerosis, while adding a new registry identifier and a revision number.SummaryDifference13%
- Check24 days agoNo Change Detected
- Check31 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and a date has been added for February 6, 2025. However, there are no significant changes in core content, pricing, or availability.SummaryDifference0.2%
- Check38 days agoChange DetectedThe page has been updated to reflect a new last update date of March 25, 2025, and a revision change to version 2.14.3, replacing the previous date of February 6, 2025, and version 2.14.2.SummaryDifference0.1%
- Check66 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference0.7%
- Check88 days agoChange DetectedThe page has been updated to reflect new dates for optional extension periods for young participants with teriflunomide, moving from 2024 to 2025, indicating a significant change in the timeline for these participants. Additionally, there is a notice regarding heavy traffic affecting NLM-NCBI services.SummaryDifference1%
Stay in the know with updates to Teriflunomide in Pediatric MS Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Teriflunomide in Pediatric MS Clinical Trial page.